Skip to main content
. 2022 Jun 2;12(1):189–199. doi: 10.1002/cam4.4906

TABLE 2.

Summary of hazard ratio for overall survival outcome for nivolumab compared to sorafenib across different analyses

Univariable model Multivariable model IPTW model
HR (95% CI) 0.86 (0.66–1.13) 0.69 (0.52–0.91) 0.77 (0.55–1.06)

Abbreviations: CI, confidence interval; HR, hazard ratio; IPTW, inverse probability of treatment weighting.